BPC — Precision Peptide Cashflow Statement
0.000.00%
Last trade - 00:00- CA$16.46m
- CA$15.50m
- CA$0.05m
Annual cashflow statement for Precision Peptide, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.173 | -1.13 | -1.66 | -1.03 | -4.53 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | — | 0.11 | 0.432 | 0.219 | 2.25 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.357 | 0.263 | 0.24 | 0.369 | -0.144 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.53 | -0.719 | -0.981 | -0.439 | -2.33 |
| Capital Expenditures | -0.061 | -0.007 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | — | -0.27 |
| Acquisition of Business | |||||
| Cash from Investing Activities | -0.061 | -0.007 | 0 | — | -0.27 |
| Financing Cash Flow Items | -0 | 0 | — | — | 0.005 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.4 | -0.001 | 0.956 | 0.528 | 3.41 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.808 | -0.732 | -0.024 | 0.088 | 0.82 |